{"nctId":"NCT01934972","briefTitle":"A Randomized Controlled Trial of Cognitive Remediation and D-cycloserine for Individuals With Bipolar Disorder","startDateStruct":{"date":"2013-03","type":"ACTUAL"},"conditions":["Bipolar Disorder"],"count":30,"armGroups":[{"label":"CR + DCS","type":"EXPERIMENTAL","interventionNames":["Other: CR + DCS (D-cycloserine)"]},{"label":"CR + placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Other: CR + placebo"]}],"interventions":[{"name":"CR + DCS (D-cycloserine)","otherNames":["DCS and Cognitive Remediation"]},{"name":"CR + placebo","otherNames":["Cognitive Remediation"]}],"eligibilityModule":{"eligibilityCriteria":"\\- Inclusion Criteria: \\[i\\] Diagnosis of Bipolar I or Bipolar II Disorder determined by the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders (DSM) \\[ii\\] Ages 18-65 \\[iii\\] No evidence of mental retardation, dementia, or other organic disorder that may reduce cognitive functioning \\[iv\\] premorbid intelligence quotient (IQ) greater than or equal to 70 as determined by reading subtest of the Wide Range Achievement Test.\n\n\\[v\\] Able to provide informed consent as evidenced by passing the informed consent quiz with a score of 80% or greater.\n\n\\[vi\\] Fluent in English as assessed per self-report from participant \\[vii\\] Female subjects cannot be pregnant or breastfeeding. All subjects must consent to using at least one form of birth control during study participation.\n\n\\[viii\\] Current remission of depressive symptoms as indicated by a score of 8 or less on the Bipolar Depression Rating Scale.\n\n\\[ix\\] Current remission of manic symptoms as indicated by a score of 7 or less on the Young Mania Scale\n\nExclusion criteria:\n\n\\[i\\] Hypersensitivity to previous receipt of cycloserine per subject report \\[ii\\] Epilespy or history of seizures as assessed using the Medical History form \\[iii\\] Meets DSM-IV criteria for alcohol or drug abuse in the past month or dependence in the past three months.\n\n\\[iv\\] Active suicidal or homicidal ideation \\[v\\] Initiation or increase in dosage of any antidepressant within six weeks, or mood stabilizer within four weeks as assessed using the Medication Checklist.\n\n\\[vi\\] Previous or current participation in cognitive remediation per subject report \\[vii\\] Currently taking d-cycloserine \\[viii\\] Reduced kidney or liver functioning, vitamin B12 deficiency, folic acid deficiency, megaloblastic anemia, or sideroblastic anemia per baseline safety labs.\n\n\\[ix\\] Currently taking medication known to have problematic interactions with d-cycloserine, including etionamide and isoniazid.\n\n\\[x\\] History of the blood disease porphyria as assessed using the Medical History form \\[xi\\] Current active symptoms of psychosis defined as not meeting existing guidelines \\[12\\] for remission of psychotic symptoms using the Positive and Negative Syndrome Scale.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Cognitive Functioning","description":"Level of cognitive functioning will be assessed via overall cognitive composite score from the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery. Scores on the MATRICS are presented at T-scores with a mean of 50 and standard deviation of 10 as compared to a normative sample. The possible range of scores are 0-100. Higher scores are indicative of better cognitive functioning.\n\nChange from baseline in cognitive functioning was calculated by taking the MATRICS overall cognitive functioning score at 26-week follow-up and subtracting the MATRICS overall cognitive composite score from baseline. Positive values on this score are indicative of improvements in cognitive functioning from baseline.\n\nMissing values on the MATRICS were addressed using multiple imputation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.90","spread":"22.02"},{"groupId":"OG001","value":"7.12","spread":"8.72"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Manic Symptomatology","description":"Manic symptomatology assesed using the Yung Mania Scale. Total scores on this scale range from 0 to 60 with higher scores indicative of greater severity of manic symptoms. Change scores from baseline were calculated by subtracting baseline total scores on this measure from 26-week scores. For this change score, positive values indicate that manic symptom severity was worse at 26-week follow-up than at baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.27","spread":"31.39"},{"groupId":"OG001","value":"-0.25","spread":"6.60"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Depressive Symptomatology","description":"Depressive symptomatology assessed using the Inventory of Depressive Symptomatology (Clinician-Rated). Total scores on this measure range from 0-84 with higher scores indicative of worse depressive symptomatology. Change from baseline in depressive symptomatology was calculated by subtracting baseline scores on the Inventory of Depressive Symptomatology from 26-week scores on this measure. Positive values of this change score indicate that depressive symptoms were worse at 26-week assessment than at baseline assessment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.25","spread":"1.26"},{"groupId":"OG001","value":"2.67","spread":"8.08"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Social Functioning","description":"Social functioning assessed using the Social Functioning Scale. Total score calculated by converting all subscale scores to a standard score with mean = 100 and standard deviation = 15. These subscale scores are then averaged to calculate the total score. There is no set minimum or maximum on this scale given this scoring procedure.\n\nChange from baseline in social functioning was calculated by subtracting total scores at baseline assessment from total scores at 26-week. A positive value on this change score are indicative of better social functioning at 26-week assessment than at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.87","spread":"51.63"},{"groupId":"OG001","value":"30.85","spread":"52.78"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Functional Capacity","description":"Functional capacity assessed using the Brief University of California, San Diego Performance-Based Skills Assessment (UPSA). Scores range from 0-100 with higher scores indicative of greater functional capacity.\n\nChange score were calculated by subtracting baseline scores on the UPSA from scores from the 6-month assessment. Positive values are indicative of higher functional capacity at 26-week follow-up as compared to baseline assessment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.59","spread":"11.42"},{"groupId":"OG001","value":"-9.26","spread":"24.79"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline in Health-related Quality of Life","description":"Health-related quality of life assessed using the RAND 36-Item Health Survey. Data are converted to Quality Adjusted Life Years (QALY) which has a minimum of 0 and a maximum of 1. Higher scores are indicative of greater health-related quality of life.\n\nChange scores are calculated by subtracting baseline scores from scores from 26-week assessment. Positive values on this change score indicate that health-related quality of life was higher at 26-weeks than baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.06"},{"groupId":"OG001","value":"0.11","spread":"0.10"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline in Medication Adherence","description":"Medication adherence assessed using the Medication Adherence Rating Scale. Higher scores on this measure are indicative of worse medication adherence. Scores on this scale range from 0-10.\n\nChange scores were calculated by subtracted scores on this measure at baseline from scores at 26-week assessment. Positive values on this change score are indicative of worse medication adherence at 26-week follow-up as opposed to baseline assessment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"1"},{"groupId":"OG001","value":"0.5","spread":"0.58"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline in Quality of Life","description":"Quality of life assessed using the World Health Organization Quality of Life Scale. A total score was calculated by averaging scores for the four subscales on this measure. Range for this total score is 0-100 with higher scores indicative of greater quality of life.\n\nChange scores were calculated by subtracting baseline scores on this measure from week-26 scores. Positive values for this change score indicate the quality of life scores were greater at week 26 than at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.75","spread":"8.23"},{"groupId":"OG001","value":"7.92","spread":"4.06"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline in Stage of Recovery","description":"Stage of recovery assessed using the Stages of Recovery Instrument. This instrument identifies which phase of recovery the participant identifies themselves to be within: moratorium, awareness, preparation, rebuilding, and growth. Outcome presented in the number of participants identifying as being within the growth phase of recovery at 26-week followup","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline in Metacognition","description":"Metacognition assessed using the Metacognitive Awareness Inventory. Total scores on this measure range from 0-100 with higher scores indicative of greater metacognition.\n\nChange in metacognition from baseline was calculated by subtracting baseline total scores on this measure from total scores on this measure at 26-week assessment. Positive values on this change score indicate that metacognition scores were higher at 26-week assessment than at baseline assessment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.56","spread":"48.22"},{"groupId":"OG001","value":"57.04","spread":"5.88"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change in Instrinsic Motivation From Baseline","description":"Intrinsic motivation assessed using the Intrinsic Motivation Inventory (IMI). Scores on this measure range from 21-147 with higher scores indicative of greater intrinsic motivation. For the current study, we asked specifically about intrinsic motivation to participate in CR.\n\nChange scores were calculated by subtracting baseline total scores on this measure from total scores obtained at 26-week assessment. Positive values on this change score indicate that participants reported greater intrinsic motivation as 26-week assessment as compared to baseline assessment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.5","spread":"12.02"},{"groupId":"OG001","value":"7.67","spread":"4.04"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Frequency of Side Effects During Study Participation","description":"Assessed using the Systematic Assessment for Treatment Emergent Events. Number of participants who endorsed an adverse event during study participation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":13},"commonTop":[]}}}